For nearly a century we have been aware of the metabolic reprogramming that takes place in tumor cells (6), and this has resulted in the development of drugs that target tumor cell metabolism e.g., methotrexate, an inhibitor of dihydrofolate reductase, that has been used in chemotherapy since the 1940s (7). This evidence concerns the gene DHFR and neoplasm.